This Activity Requires You To Leave myCME.

You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.

You are about to open a webpage that is outside of this educational content.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
This CME Activity has expired and is no longer available for credit.
Clinical Challenges and Renal Considerations in Managing Gout: Part I

Clinical Challenges and Renal Considerations in Managing Gout: Part I

Format

Clinical Review

Time to Complete

1.00 Hour

Released

March 6, 2012

Expires

March 31, 2013

Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM
1.00 / AAFP Prescribed Credit
1.00 / CE for Nurses
1.00 / CE for Pharmacists

Accredited Provider

Medical Education Resources and Haymarket Medical Education jointly sponsor this activity.

If you have any questions relating to the accreditation of this activity, please contact:

Medical Education Resources, Inc.
1500 West Canal Court
Littleton, CO 80120-5615
Tel: 1-800-421-3756
E-mail: info@cmepartner.org
Commercial Supporter
This activity is supported by an educational grant from Savient Pharmaceuticals.

Program Description

Hyperuricemia and gout are common among renal transplant recipients and present challenges to the management of both immunosuppression and high uric acid levels. The relatively high prevalence of hyperuricemia and gout in this patient population are attributable to abnormal renal urate transport mechanisms due to the use of calcineurin inhibitors and/or intrinsic renal tubular defects. The risks and benefits of pharmacologic agents used to treat acute attacks of gout and chronic hyperuricemia must be evaluated carefully for their effects on serum uric acid levels and drug-drug interactions.

Intended Audience

This activity has been designed to meet the educational needs of nephrologists and other clinicians involved in the treatment of patients with gout.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Describe how renal function affects the management of gout.
  • Evaluate current and emerging options for urate-lowering therapy with regard to their benefits and limitations in patients with varying degrees of renal impairment.
  • Discuss ways to motivate patient adherence to a long-term treatment plan that incorporates lifestyle considerations and pharmacotherapy.

Statement of Need

Clinicians today face an increasing number of patients with gout. Nephrologists in particular must contend with complex cases in patients with varying degrees and stages of renal dysfunction in addition to other comorbidities and individual characteristics that affect treatment decisions and, ultimately, treatment success. As gout occurs in tandem with renal disorders, nephrologists must be able to appropriately identify and treat these patients.

Disclosure of Conflicts of Interest

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.

Faculty

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

William F. Finn, MD
Professor of Medicine
Division of Nephrology and Hypertension
University of North Carolina School of Medicine
at Chapel Hill

William F. Finn, MD
Consultant: Takeda Pharmaceuticals
Speakers’ Bureau: Takeda Pharmaceuticals

Anthony J. Bleyer, MD (Faculty Chair)
Professor of Medicine
Section of Nephrology
Wake Forest University School of Medicine
Winston-Salem, NC

Anthony J. Bleyer, MD
Consultant: Takeda Pharmaceuticals, Savient Pharmaceuticals

Publishing Staff Disclosures

The content managers, Marjorie Hale, Jill Rovitzky Black, Susan Basilico, Jody A. Charnow and Marina Galanakis of Haymarket Medical Education, and Victoria C. Smith, MD, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest relating directly or indirectly to this activity.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Media, Inc. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Medical Education Resources designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Medical Education Resources, Inc. (MER), and Haymarket Medical Education (HME) do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of MER and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Savient Pharmaceuticals, Inc., Medical Education Resources or Haymarket Media, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Savient Pharmaceuticals, Inc., Medical Education Resources, or Haymarket Media, Inc. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Instructions

To obtain credit, a post-test score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Add to Queue